Scientifically Proven: The Nima Sensor Can Improve the Quality of Life for Those with Celiac Disease

Tuesday, April 2, 2019 Medical Gadgets
Email Print This Page Comment bookmark
Font : A-A+

90% of study participants agreed that The Nima Sensor was easy to understand, helped them follow a gluten-free diet, gave peace of mind & was useful.

SAN FRANCISCO, April 2, 2019 /PRNewswire-PRWeb/ -- Today, Nima, the pioneer in connected food sensors, announced that

a recently published quality of life study has scientifically proven that the Nima Sensor helped lower depression among adult participants in a statistically significant manner.

This study was recently published in the journal of Clinical Gastroenterology and Hematology and tested the effects of using the Nima Gluten Sensor on quality of life and adherence to a strict gluten-free diet. The study found that "over 90% of participants agreed that Nima was easy to understand, helped them follow a gluten-free diet, gave peace of mind & was useful." (Wolf et al, 2019)

As many who have Celiac disease or care for someone with the disease might suspect, quality of life often diminishes when on a strict gluten-free diet. The burden of treatment for Celiac disease is high for patients – comparable to the burden of patients with end stage renal disease on dialysis. (Shah et al, 2014)

To read a summary of the quality of life study click here To access the full study, click here.

"We are thrilled to see that the support Nima was developed to provide to the Celiac community is being tested and validated with studies like this." said Shireen Yates, CEO and co-founder of Nima. "We look forward to sharing more studies highlighting Nima as they are published and will provide them to the community as soon as they are published."

Over 15 million Americans suffer from food allergies and 3 million suffer from Celiac Disease, making it potentially dangerous to eat foods they haven't prepared themselves. Nima's revolutionary Gluten Sensor and Peanut Sensor are the first, and only, pocket-sized devices that allows those with dietary restrictions to quickly test their food for allergens in a few minutes and at the dining table for added peace of mind at meal time. Users are encouraged to always practice due diligence

"Nima is not designed to replace any of the precautions people with food allergies or sensitivities are already taking at mealtime," Yates said. "Our program is designed to provide one additional data point for our customers using Nima to test samples of their dishes at mealtime, in addition to all the other precautions they already take"

This quality of life study was run with 30 participants (15 adults and 15 teenagers) for a period of three months. The study concluded that "The vast majority of participants would recommend the device to others with Celiac disease and planned to continue using it." (Wolf et al, 2019)


About Nima Founded in 2013, Nima is a science-driven technology company making the world safer for people who want and need to know what's in their food. Through people-friendly products that identify individual ingredients in food, and a growing community of users and data, every day Nima enables people to enjoy what's on their plates. Co-founders Shireen Yates and Scott Sundvor created Nima out of personal experience with food intolerances. To date, Nima has raised more than $15 million, including financing from Foundry Group, Upfront Ventures, SoftTech VC, SK Ventures and Lemnos Labs, with additional federal grants from the National Institutes of Health. For more Nima news, visit our blog or press section.

References: Sveta Shah;Mona Akbari;Rohini Vanga;Ciaran Kelly;Joshua Hansen;Thimmaiah Theethira;Sohaib Tariq;Melinda Dennis;Daniel Leffler, Patient Perception of Treatment Burden Is High in Celiac Disease Compared With Other Common Conditions, American Journal of Gastroenterology. 109(9):1304–1311, SEP 2014, doi: 10.1038/ajg.2014.29

Wolf RL, Green PHR, Lee AR, Reilly NR, Zybert P, Lebwohl B, Benefits From and Barriers to Portable Detection of Gluten, Based on a Randomized Pilot Trial of Patients with Celiac Disease, Clinical Gastroenterology and Hepatology (2019), doi: 10.1016/j.cgh.2019.03.011.



Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store